Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 262 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Demyelinating Autoimmune Diseases, Central Nervous System (CNS) Clear all
Completed Phase 4 Interventional

Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis

NCT00381264
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cesamet™ (nabilone)
Drug
Lead sponsor
NEMA Research, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Aventura, Florida • Hollywood, Florida • Naples, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Oct 21, 2026, 10:13 PM EDT
Terminated No phase listed Observational

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

NCT01156298
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 21, 2026, 10:13 PM EDT
Enrolling by invitation Not applicable Interventional

Effects of Stimulation Patterns of Deep Brain Stimulation

NCT02553525
View directory record Official record
Conditions
Parkinson Disease, Essential Tremor, Multiple Sclerosis, Dystonia
Interventions
Therapeutic Stimulation Patterns, Symptogenic Stimulation Patterns
Procedure
Lead sponsor
Duke University
Other
Eligibility
21 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 10:13 PM EDT
Completed No phase listed Observational

International Guillain-Barré Syndrome Outcome Study

NCT01582763
View directory record Official record
Conditions
Guillain-Barré Syndrome, Miller Fisher Syndrome
Interventions
Not listed
Lead sponsor
Erasmus Medical Center
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 21, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Telehealth Pain Self-Management for Employed Adults

NCT04248725
View directory record Official record
Conditions
Chronic Pain, Brain Injuries, Traumatic, Multiple Sclerosis, Spinal Cord Injuries, Amputation
Interventions
E-TIPS
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 21, 2026, 10:13 PM EDT
Enrolling by invitation No phase listed Observational

Serum Auto-Antibodies in Neurological Diseases

NCT00704626
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
Interventions
Blood Draw, Cheek swab
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2031
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 10:13 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 21, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

NCT00071838
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:13 PM EDT
Recruiting Not applicable Interventional

Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study

NCT07759115
View directory record Official record
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Music Training Intervention, Music Listening
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 10:13 PM EDT
Recruiting Phase 1 Interventional

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT05849467
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
Interventions
89 Zr-Df-crefmirlimab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

NCT04201262
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 21, 2026, 10:13 PM EDT
Completed No phase listed Observational

Cognitive Testing for the Pain Quality Assessment Scale (PQAS)

NCT00715598
View directory record Official record
Conditions
Pain, Spinal Cord Injuries, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 21, 2026, 10:13 PM EDT
Completed No phase listed Observational

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

NCT02099370
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 21, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Behavior and Activity Monitoring in MS

NCT03244696
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Step Tracking, Water Tracking
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
30 Years to 59 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 21, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04667117
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Quadrivalent influenza vaccine, Ofatumumab, iDMT
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 21, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Lakeshore Examination of Activity and Disability Exercise Response Study

NCT02533882
View directory record Official record
Conditions
Multiple Sclerosis, Stroke
Interventions
Movement to Music, Adapted Yoga
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 21, 2026, 10:13 PM EDT
Completed No phase listed Observational

Multi-center Database Registry to Study Thalamus Changes Using AI in MS

NCT03920995
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 21, 2026, 10:13 PM EDT
Active, not recruiting Phase 2 Interventional

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

NCT06384976
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
Interventions
KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB
Biological · Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 21, 2026, 10:13 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

NCT03759522
View directory record Official record
Conditions
Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
Interventions
DPA-714 PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 10:13 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

NCT07222956
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Interventions
Remibrutinib (Open Label)
Drug
Lead sponsor
Moein Amin
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients

NCT02184494
View directory record Official record
Conditions
Parkinson's Disease, Multiple Sclerosis
Interventions
pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
Device
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 21, 2026, 10:13 PM EDT
Completed No phase listed Observational

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

NCT04495556
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

NCT01953523
View directory record Official record
Conditions
Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions
Administration of autologous adipose derived SVF
Procedure
Lead sponsor
Elliot Lander
Industry
Eligibility
16 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

NCT07840326
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions
SUN-627, Placebo
Drug · Other
Lead sponsor
Sundance Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Raleigh, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 10:13 PM EDT